Abbott’s oral Hep C drugs ABT-450 and ABT-333 bring some exciting news in Phase II.


In a presentation released at the European Association for the Study of the Liver (EASL) meeting, a combination regimen including the oral drugs ABT-450 and ABT-333 resulted in cure rates of over 90% in 50 patients which had previously been untreated. Quite remarkable results indeed and larger mid-stage trials using various combinations of the experimental drugs are now underway. Abbott has said it would look to sell a new HCV regimen in 2015 under the AbbVie spin-off. The EASL meeting, which is being held April 18-22, is always a hotbed of activity for the new Hep C drugs and a very insightful update can in fact be found on  What is on everyone's mind is the interim results from a phase II study combining Bristol-Myers Squibb's NS5a inhibitor daclatasvir (BMS-52) with Gilead's GS-7977. If this study proves effective it has been indicated that BMS will replace the GS-7977 with INX-189, a experimental drug acquired from the Inhibitex acquistion at the beginning of this year.

If you want to do anymore homework on the new therapies being studied, there is a very comprehensive list at –

Leave a Reply

Your email address will not be published. Required fields are marked *